| HOME >> BIOLOGY >> TECHNOLOGY |
Retained earnings 9,323,261
Accumulated other comprehensive income 1,008,074
Total Stockholders' Equity 15,725,280
Total Liabilities and Stockholders' Equity $18,887,829
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(UNAUDITED)
Six Months Ended Three Months Ended
December 31, December 31,
2007 2006 2007 2006
SALES $14,918,692 $8,210,022 $7,749,199 $4,344,846
COST OF GOODS SOLD 8,861,258 5,091,764 4,567,429 2,702,593
GROSS PROFIT 6,057,434 3,118,258 3,181,770 1,642,253
EXPENSES
Selling, general and
administrative 2,200,541 801,776 1,172,062 457,519
Research and
development 61,558 13,380 34,106 6,269
Total Expenses 2,262,099 815,156 1,206,168 463,788
INCOME FROM OPERATIONS 3,795,335 2,303,102 1,975,602 1,178,466
OTHER INCOME (EXPENSES)
Other income -- 1,432 --
Interest expense (66,362) (71,745) (31,659) (36,604)
Total Other Income
(Expenses) (66,362) (70,313) (31,659) (36,604)
INCOME BEFORE PROVISION FOR
INCOME TAX 3,728,973 2,232,789 1,943,943 1,141,862
PROVISION FOR INCOME TAX 556,646 310,936 291,572 155,545
NET INCOME 3,172,327 1,921,853 1,652,371 986,317
OTHER COMPREHENSIVE INCOME
Foreign currency
translation ad
'/>"/>
| SOURCE Tianyin Pharmaceutical, Inc. Copyright©2008 PR Newswire. All rights reserved |